2023.06.29 CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
2021.03.06 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies
2020.03.14 Claudin 18.2 – 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation
